| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8454365 | Lung Cancer | 2017 | 11 Pages |
Abstract
This review will summarise the rationale to target DNA damage response in SCLC, the progress made in evaluating novel DDR inhibitors and highlight various ongoing challenges for their clinical development in this disease.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Victoria Foy, Maximilian W. Schenk, Katie Baker, Fabio Gomes, Alice Lallo, Kristopher K. Frese, Martin Forster, Caroline Dive, Fiona Blackhall,